Articles by tag: bevacizumab

FDA approved the first ophthalmic bevacizumab LYTENAVA for the treatment of wet AMD

FDA accepted Outlook Therapeutics' appeal and will approve LYTENAVA — a standardized bevacizumab for neovascular AMD. Analysis of consequences for the anti-VEGF market, pricing, and patients. Read more.

FDA approves expansion of Avastin biosimilar production

FDA approves expansion of Avzivi biosimilar production to 4000 L. Learn how this will lower bevacizumab prices and reshape the market. Detailed analysis.

FDA may approve ophthalmic bevacizumab Lytenava

Analysis of the regulatory paradox: why the FDA rejected it three times, while Europe approved it. Learn how the Lytenava decision will change the $16 billion AMD market.